FDA approves Bravecto Quantum from Merck Animal Health

European Commission fines Alchem for participating in API cartel

The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle

RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer

Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.

Astellas and Pfizer’s XTANDI shows overall survival in metastatic hormone-sensitive prostate cancer

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%

Venus Remedies secures Ukrainian GMP renewal

Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards

CuraTeQ Biologics completes Phase 1 Pharmacokinetics study of biosimilar Denosumab

This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets

European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults

Lucas Meyer Cosmetics by Clariant to launch honey-based skin repair solution ‘Melicica’

Melicica has potential applications in skin repair, scar and acne-prone skin care, tone evening and brightening, texture improvement, baby care, sensitive skin solutions, post-procedure recovery and stretch mark care

Wockhardt’s Zaynich achieves highest-ever efficacy meeting superiority in a global, pivotal, registration- enabling Phase III study

Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years

Calquence combination approved in US for untreated mantle cell lymphoma

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone